Literature DB >> 2787758

Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas.

S Miki1, M Iwano, Y Miki, M Yamamoto, B Tang, K Yokokawa, T Sonoda, T Hirano, T Kishimoto.   

Abstract

Interleukin-6 (IL-6) was found to be a growth factor of renal cell carcinomas Furthermore, renal cell carcinomas freshly isolated from the patients expressed mRNA of IL-6 and secreted biologically active IL-6 under the culture conditions where the tumor cells could grow, but they did not produce IL-6 nor proliferate in the absence of fetal calf serum. The production of IL-6 by the tumor cells was also demonstrated by immunostaining of the IL-6-producing cells utilizing anti-IL-6 antiserum. Moreover, anti-IL-6 antiserum specifically inhibited the in vitro tumor growth. All data indicated that IL-6 functions as an in vitro autocrine growth factor of renal cell carcinomas.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787758     DOI: 10.1016/0014-5793(89)80805-1

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  94 in total

Review 1.  BCG response prediction with cytokine gene variants and bladder cancer: where we are?

Authors:  Dinesh Kumar Ahirwar; Parmeet Kaur Manchanda; Rama Devi Mittal; Hemant K Bid
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-20       Impact factor: 4.553

2.  IL-6 increases MMP-13 expression and motility in human chondrosarcoma cells.

Authors:  Chih-Hsin Tang; Cheng-Fong Chen; Wei-Ming Chen; Yi-Chin Fong
Journal:  J Biol Chem       Date:  2011-01-28       Impact factor: 5.157

3.  An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification.

Authors:  Owen W Stephens; Qing Zhang; Pingping Qu; Yiming Zhou; Shweta Chavan; Erming Tian; David R Williams; Joshua Epstein; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

4.  Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer.

Authors:  Christopher Johnson; Yuyan Han; Nathan Hughart; Jennifer McCarra; Gianfranco Alpini; Fanyin Meng
Journal:  Transl Gastrointest Cancer       Date:  2012-04-01

5.  Peptide inhibitors of MK2 show promise for inhibition of abdominal adhesions.

Authors:  Brian C Ward; Sandra Kavalukas; Jamie Brugnano; Adrian Barbul; Alyssa Panitch
Journal:  J Surg Res       Date:  2011-02-23       Impact factor: 2.192

6.  Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.

Authors:  Hironori Fukuda; Toshio Takagi; Tsunenori Kondo; Kazuhiko Yoshida; Satoru Shimizu; Yoji Nagashima; Kazunari Tanabe
Journal:  Int J Clin Oncol       Date:  2018-01-05       Impact factor: 3.402

7.  Interleukin-6 mediates G(0)/G(1) growth arrest in hepatocellular carcinoma through a STAT 3-dependent pathway.

Authors:  Dairmuid M Moran; M Adrian Mattocks; Paul A Cahill; Leonidas G Koniaris; Iain H McKillop
Journal:  J Surg Res       Date:  2007-06-14       Impact factor: 2.192

8.  Interleukin-6 and interleukin-6 receptor gene expression in pituitary tumors.

Authors:  A R Rezai; A Rezai; O Martínez-Maza; M Vander-Meyden; M H Weiss
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

9.  Interleukin-6 and acute-phase proteins in head and neck cancer.

Authors:  O Gallo; A M Gori; M Attanasio; F Martini; B Giusti; T Brunelli; E Gallina
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

10.  Interleukin-6 stimulates cell proliferation of rat pituitary clonal cell lines in vitro.

Authors:  T Sawada; K Koike; Y Kanda; H Ikegami; H Jikihara; T Maeda; Y Osako; K Hirota; A Miyake
Journal:  J Endocrinol Invest       Date:  1995-02       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.